Gastroenteric pathology and probiotics: From myth to scientific evidence. Current aspects;Patologia gastroenterica e probiotici: Dal mito alle evidenze scientifiche. Aspetti attuali

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 3, 2009, Pages 237-272

  Caramia, G ^a  

^a G Salesi Specialized Hospital for Mothers and Children   (Italy)

Author keywords

Anti bacterial agents; Gastrointestinal diseases; Probiotics

Indexed keywords

PROBIOTIC AGENT;

CLOSTRIDIUM DIFFICILE; DRUG EFFICACY; DRUG MECHANISM; DYSBIOSIS; ENTERITIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HISTORY OF MEDICINE; INFECTIOUS DIARRHEA; INTESTINE MUCOSA; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; MICROFLORA; NECROTIZING ENTEROCOLITIS; REVIEW; TRAVELLER DIARRHEA;

DIARRHEA; ENTEROCOLITIS, NECROTIZING; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; PROBIOTICS; TRAVEL;

EID: 75749156673     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Metchnikoff E. The Prolongation of life. Optimistic studies. William. Heinemann, London; 1907.
2. Vergin F. Antibiotics and probiotics. Hippokrates 1954;25:116-9.
3. Lilly DM, Stillwell RH. Probiotics: Growth-promoting factors produced by microorganisms. Science 1965;147:747-8.
4. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006;118:511-21.
5. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80(Suppl 1):S147-71.
6. Hopkins MJ, Sharp R, Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 2001;48:198-205.
7. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-9.
8. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 2000;30:61-7.
9. Caramia G. I Probiotici: da Metchnikoff alle attuali possibilità preventive e terapeutiche Ped Med Chir 2004;26:19-33.
10. Parracho H, McCartney AL, Gibson GR. Probiotics and prebiotics in infant nutrition. Proc Nutr Soc 2007;66:405-11.
11. Sigal LH. Basic science for the clinician 26: Tolerance - mechanism and manifestation. J Clin Rheumatol 2005;11:113-7.
12. Sigal LH. Basic science for the clinician 32: T-cells with regulatory function. J Clin Rheumatol 2005;11:286-9.
13. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis M, Akdis CA et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006;117:433-42.
14. Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Felicita Study Group. Pediatr Res 2007;62:215-20.
15. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosac-charide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009;29:508-18.
16. Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D.Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008;10:37-54.
17. Zoetendal EG, Akkermans AD, Akkermans-Van Vliet WM, de Visser AGM, de Vos WM. The host genotype affects the bacterial community in the human gastrointestinal tract. Microb Ecol Health Dis 2001;13:129-34.
18. Tancrède C. Role of human microflora in health and disease. Eur J Clin Microbiol Infect Dis 1992;11:1012-5
19. Neish AS. The gut microflora and intestinal epithelial cells: a continuing dialogue. Microbes Infect 2002;4:309-17.
20. Mordenti AL. Microflora del digerente e salute. In: Cocchi M, Mordenti A, editors. Alimenti e salute. Bologna: Ed. Clueb; 2005. p. 457-74.
21. Zuccotti GV, Meneghin F, Raimondi C, Dilillo D, Agostoni C, Riva E et al. Probiotics in clinical practice: an overview. J Int Med Res 2008;36(Suppl 1):1A-53A.
22. Martin FP, Wang Y, Sprenger N, Yap IK, Lundstedt T, Lek P et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008;4:157
23. Mackie RI, Sghir A, Gaskins HR. Developmental micro-bial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 1999;69:1035S-1045S.
24. Snel J, Harmsen HJ, Van der Wielen PW, Williams BA. in Nutrition and health of gastrointestinal tract - Wageningen Academic Publisher 2002;37-9.
25. Calder PC, Krauss-Etschmann S, de Jong EC, Dupont C, Frick JS, Frokiaer H et al. Early nutrition and immunity - progress and perspectives. Br J Nutr 2006;96:774-90.
26. Castellazzi AM, Valsecchi C, Montagna L, Malfa P, Ciprandi G, Avanzini MA et al. In vitro activation of mononuclear cells by two probiotics: Lactobacillus paracasei I 1688, Lactobacillus salivarius I 1794, and their mixture (PSMIX). Immunol Invest 2007;36:413-21.
27. - Björkstén B. Environmental influences on the development of the immune system: consequences for disease outcome. Nestle Nutr Workshop Ser Pediatr Program. 2008;61:243-54.
28. Conroy ME, Walker WA. Intestinal immune health. Nestle Nutr Workshop Ser Pediatr Program 2008;62:111-21.
29. Cummings J.H., Macfarlane G.T. Colonic microflora: nutrition and health. Nutrition 1997;13:476-8.
30. Zuppa AA, Savarese I, Scorrano A, Calabrese V, D'Andrea V, Fracchiolla A et al. Prebiotics and probiotics in infant nutrition. Pediatr Med Chir 2007;29:69-83.
31. Caramia G, Atzei A, Fanos V. Probiotics and the skin. Clinics in Dermatology 2008;26:4-11.
32. Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol 2008;606:423-54.
33. Geier MS, Butler RN, Howarth GS. Probiotics,prebiotics and synbiotics:a role in chemoprevention for colorectal cancer? Cancer Biol Ther 2006;5:1265-9.
34. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008;46(Suppl 2):S87-91.
35. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: Recent advances. Inflamm Bowel Dis 2009;15:300-10.
36. Otte JM, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. Probiotics Regulate the Expression of COX-2 in Intestinal Epithelial Cells. Nutr Cancer 2009;61:103-13.
37. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002;277:50959-65.
38. Shi HN, Walker WA. Bacterial colonization and the development of intestinal defenses. Can J Gastroenterol 2004;18:493-500.
39. Kohler H, McCormick BA, Walker WA. Bacterial-enterocyte crosstalk: cellular mechanisms in health and disease. J Pediatr Gastroenterol Nutr 2003;36:175-85.
40. Kligler B, Hanaway P, Cohrssen A. Probiotics in children. Pediatr Clin N Am 2007;4:949-67.
41. Renz H, Blumer N, Virna S, Sel S, Garn H. The immunological basis of the hygiene hypothesis. Chem Immunol Allergy 2006;91:30-48.
42. Hauer A. Probiotics in allergic diseases of childhood. MMW Fortschr Med 2006;148:34-6.
43. Guarner F, Bourdet-Sicard R, Brandtzaeg P, Gill HS, Gill HS, McGuirk P, van Eden W et al. Mechanisms of disease: the hygiene hypothesis revisited. Nat Clin Pract Gastroenterol Hepatol 2006;3:275-84.
44. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008;121:116-21.
45. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in infl ammatory bowel disease: A critical review of the literature. World J Gastroenterol 2008;14:165-73.
46. Marschan E, Kuitunen M, Kukkonen K, Poussa T, Sarnesto A, Haahtela T, Korpela R et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 2008;38:611-8.
47. Floch MH, Madsen KK, Jenkins DJ, Guandalini S, Katz JA, Onderdonk A et al. Recommendations for probiotic use. J Clin Gastroenterol 2006;40:275-8.
48. Guslandi M. A natural approach to treatment of inflammatory bowel disease. Br J Clin Pharmacol 2008;65:468-9.
49. Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora on the scope. Br J Clin Pharmacol 2008;65:453-67.
50. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008;46(Suppl 2):S96-100.
51. Doron SI, Hibberd PL, Gorbach SL. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol 2008;42(SuppI 2):S58-63.
52. Floch MH, Walker WA, Guandalini S, Hibberd P, Gorbach S, Surawicz C et al. Recommendations for probiotic use-2008. J Clin Gastroenterol 2008;42(Suppl 2):S104-8.
53. Caramia G. Metchnikoff e il centenario dei probiotici: dall'intuizione alia scienza. Ped Med Chir 2008;30:215-9.
54. Sanders ME. Use of probiotics and yogurts in maintenance of health. J Clin Gastroenterol 2008;42(Suppl 2):S71-4.
55. Guandalini S. Probiotics for children with diarrhea. An update. J Clin Gastroenterol 2008;42:S53-S57.
56. Caramia G. Metchnikoff and the centenary of probiotics: an update of their use in gastroenteric pathology during the age of development. Minerva Pediatr 2008;60:1417-35.
57. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-BiaΠek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007;25:871-81.
58. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002;109:678-84.
59. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007;335:340.
60. Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R et al. ESPGHAN/ESPID Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe Expert Working Group. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008;46:619-21.
61. Kligler B, Cohrssen A. Probiotics. Am Fam Physician 2008;78:1073-8.
62. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005;115:5-9.
63. Guarino A, Vecchio AL, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol 2009;25:18-23.
64. Spyridis N, Sharland M. The European Union Antibiotic Awareness Day: the paediatric perspective. Arch Dis Child 2008;93:909-10.
65. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004;42:1203-6.
66. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic-associated diarrhea: meta-analysis. BMJ 2002;324:1361-7.
67. Szajewska H1 Ruszczy/ski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006;149:367-72.
68. Johnston BC, Supina AL, Ospina M, Vohira S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007;2:CD004827.
69. Surawicz CM. Role of probiotics in antibiotic associated diarrhea, Clostridium difficile associated diarrhea and recurrent Clostridium difficile diarrhea. J Clin Gastroenterol 2008;42:S64-S70.
70. Pham M, Lemberg DA, Day AS. Probiotics: sorting the evidence from the myths. Med J Aust 2008;188:304-8.
71. Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R et al. Clinical features of Clostridium difficile associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol 2007;28:131-9.
72. Elliott B, Chang BJ, Golledge CL, Riley TV. Clostridium difficile-associated diarrhoea. Intern Med J 2007;37:561-8.
73. Giesemann T, Egerer M, Jank T, Aktories K. Processing of Clostridium difficile toxins. J Med Microbiol 2008;57:690-6.
74. McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections - epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009;25:24-35.
75. Katz JA. Probiotics for the prevention of antibioticas-sociated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol 2006;40:249-55.
76. Bartlett JG. New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 2009;11:21-8.
77. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22.
78. Collier-Hyams LS, Sloane V, Batten BC, Neish AS. Cutting edge: bacterial modulation of epithelial signaling via changes in neddylation of cullin-1. J Immunol. 2005;175:4194-4198.
79. Manzoni P, Mostert M, Leonessa ML, Priolo C, Farina D, Monetti C et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006;15:1735-42.
80. Neu J, Douglas-Escobar M, Lopez M. Microbes and the developing gastrointestinal tract. Nutr Clin Pract. 2007;22:174-82.
81. Hunter CJ, Upperman JS, Ford HR, Camerini V. Understanding the susceptibility of the premature infant to necrotizing enterocolitis (NEC). Pediatr Res 2008;63:117-23.
82. Martin CR, Walker WA. Probiotics: role in pathophysiology and prevention in necrotizing enterocolitis. Semin Perinatol 2008;32:127-37.
83. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. Biol Neonate 2002;82:103-8.
84. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1-7.
85. Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005;147:192-6.
86. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007;369:1614-20.
87. Alfaleh K, Bassler D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2008;CD005496.
88. Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multi-center, randomized, controlled trial. Pediatrics. 2008;122:693-700.
89. Sabbi T, De Angelis P, Dall'Oglio L. Helicobacter pylori infection in children: management and pharmacotherapy. Expert Opin Pharmacother 2008;9:577-85.
90. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007;56:772-81.
91. Raymond J, Bergeret M, Kalach N. Helicobacter pylori infection in children. Presse Med 2008;37:513-8.
92. Quaglia NC, Dambrosio A, Normanno G, Parisi A, Patrono R, Ranieri G et al. High occurrence of Helicobacter pylori in raw goat, sheep and cow milk inferred by glmM gene: A risk of food-borne infection? Int J Food Microbiol 2008;124;43-7.
93. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077-86.
94. Devanarayana NM, de Silva DG, de Silva HJ. Aetiology of recurrent abdominal pain in a cohort of Sri Lankan children. J Paediatr Child Health 2008;44:195-200.
95. Coskun S, Kasirga E, Yilmaz O, Bayindir P, Akil I, Yuksel H et al. Is Helicobacter pylori related to endothelial dysfunction during childhood? Pediatr Int 2008;50:150-153.
96. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ et al. Comparison of clinical and microbiological response to treatment of Clostridium difficUe-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008;47:56-62.
97. Kelly CP, LaMont JT. Clostridium difficile - More difficult than ever. N Engl J Med 2008;359:1932-40.
98. Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-9.
99. Gotteland M, Andrews M, Toledo M, Munoz L, Caceres P, Anziani A et al. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii LaI in children. Nutrition. 2008;24:421-6.
100. Kajander K, Myllyluoma E, Rajiliç-Stojanoviç M, Kyrönpalo S, Rasmussen M, Järvenpää S et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57.
101. Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003;22:360-6.
102. Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy-a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther. 2005;21:1263-72.
103. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137(Suppl 2):812S-8S.
104. Jonkers D, Stockbrügger R. Review article: Probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther 2007;26(Suppl 2): 133-48.
105. Tong JL, Ran ZH, Shen J, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68.
106. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009;21:45-53.
107. Selgrad M, Malfertheiner P. New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008;8:593-7.
108. McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections - epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009;25:24-35.
109. McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007;5:97-105.
110. Johnson AM, Kaushik RS, Rotella NJ, Hardwidge PR. Enterotoxigenic Escherichia coli modulates host intestinal cell membrane asymmetry and metabolic activity. Infect Immun 2009;77:341-7.
111. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. AmJ Gastroenterol 2004;99:1774-8.
112. Oksanen PJ, Salminen S, Saxelin M, Hämäläinen P, Ihantola-Vormisto A1 Muurasniemi-Isoviita L et al. Prevention of travellers' diarrhoea by Lactobacillus GG. Ann Med 1990;22:53-6.
113. Hilton E, Kolakowski P, Singer C, Smith M. Lactobacillus GG in prevention of travelers' diarrhea. J Travel Med 1997;4:41-3.
114. Briand V, Buffet P, Genty S, Lacombe K, Godineau N, Salomon J et al. Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study. Clin Infect Dis 2006;43:1170-5.
115. Takahashi O, Noguchi Y, Omata F, Tokuda Y, Fukui T. Probiotics in the prevention of traveler's diarrhea: meta-analysis. J Clin Gastroenterol 2007;41:336-7.
116. Tormo R, Polanco I, Salazar-Lindo E, Goulet O. Acute infectious diarrhoea in children: new insights in anti-secretory treatment with racecadotril. Acta Paediatr 2008;97:1008-15.
117. Romans S, Belaise C, Martin J, Morris E, Raffi A. Sindrome dell'intestino irritabile ed esperienze di abuso. Uno studio epidemiologico. NeUroGastroenterologia 2002;8:47-53.
118. Mättö J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005;43:213-22.
119. Madden JA, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. BrJ Nutr 2002;88(Suppl 1):S67-72.
120. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-94.
121. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008; 111:1-66.
122. Rana SV, Sharma S, Sinha SK, Kaur H, Sikander A, Singh K. Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from north India. Dig Dis Sci 2009;54:132-5.
123. Criblez D, Treumann T, Metzger J. Imaging studies in the diagnosis of functional abdominal disorders. Ther Umsch. 2009;66:25-30.
124. Guslandi M. Probiotic agents in the treatment of irritable bowel syndrome. J Int Med Res 2007;35:583-9.
125. Borowiec AM, Fedorak RN. The role of probiotics in management of irritable bowel syndrome. Curr Gastroenterol Rep 2007;9:393-400.
126. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978;2:653-4.
127. Spiller R, Aziz Q, Creed F Emmanuel A, Houghton L, Hungin P et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98.
128. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
129. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel DL, Moayyedi P. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastroin-testinal tract symptoms? JAMA 2008;300:1793-805.
130. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:994-1002.
131. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-61.
132. Macfarlane S, Steed H, Macfarlane GT. Intestinal bacteria and inflammatory bowel disease. Crit Rev Clin Lab Sei 2009;46:25-54.
133. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis 1998;4:29-39.
134. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
135. Fedorak RN, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2008. J Clin Gastroenterol 2008;42(Suppl 2):S97-103.
136. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11: 853-8.
137. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-8.
138. Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol. 2008;42(Suppl 3)Pt l:Slll-5.
139. Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 2007;22:1199-204.
140. Butterworth AD, lriomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;:CD006634.
141. Heilpern D, Szilagyi A. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. Rev Recent Clin Trials 2008;3:167-84.
142. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease Dig Dis Sci 2000;45:1462-4.
143. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease.Cochrane Database Syst Rev 2006;CD004826.
144. Henker J, Müller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 2008;46:874-5.
145. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8.
146. Tursi A, Brandimarte G, Giorgetti G, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004;10:P1126 -131.
147. Bibiloni R, Fedorak R, Tannock G, Madsen KL, Gionchetti P, Campieri M et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. AmJ Gastroenterol 2005;100:1539-46.
148. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-9.
149. Rembacken B, Smelling A, Hawkey P, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
150. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-23.
151. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1012-8.
152. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-74.
153. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43.
154. Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs 2006;66:1371-87.
155. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075-82
156. Collado MC, Isolauri E, Salminen S, Sanz Y. The impact of probiotic on gut health. Curr Drug Metab 2009;10:68-78.
157. Wallace B. Clinical use of probiotics in the pediatric population. Nutr Clin Pract 2009;24:50-9.
158. Ruemmele FM, Bier D, Marteau P, Rechkemmer G, Bourdet-Sicard R, Walker WA et al. Clinical evidence for immunomodulatory effects of probiotic bacteria. J Pediatr Gastroenterol Nutr 2009;48:126-41.
159. Sherman PM, Ossa JC, Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr Clin Pract 2009;24:10-4.